All In Biotech

Drug Trial Radar · NCT06631287

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Nov 1, 2026

Study completion Jul 1, 2027

Sponsor

Lead sponsor
Wes ElyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Institute on Aging (NIA)
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

Conditions

  • Long COVID
  • Sars-CoV-2 Infection
  • Coronavirus Infections
  • COVID-19

Interventions

  • BaricitinibDrug

    4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.

  • PlaceboOther

    Matched placebo capsule, PO once daily for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CNS-Vital Signs Global Cognitive IndexTime frame: Month 6

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona · Recruiting

  • University of California, Los Angeles (UCLA)

    Los Angeles, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • University of Colorado I Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Florida College of Medicine

    Gainesville, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Illinois Research Network (ILLInet), University of Illinois Chicago

    Chicago, Illinois · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • NYU Langone Health - Brooklyn

    Brooklyn, New York · Recruiting

  • University Hospitals Cleveland Case Western

    Cleveland, Ohio · Recruiting

  • The MetroHealth System

    Cleveland, Ohio · Recruiting

  • Vanderbilt University Medical

    Nashville, Tennessee · Recruiting

  • University of Texas at San Antonio

    San Antonio, Texas · Recruiting

  • Swedish Medical Center

    Seattle, Washington · Recruiting

  • West Virginia Clinical and Translational Science Institute

    Morgantown, West Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.